Literature DB >> 12202878

Tumor necrosis factor-alpha production in whole blood after cardiopulmonary bypass: downregulation caused by circulating cytokine-inhibitory activities.

J Börgermann1, I Friedrich, S Flohé, J Spillner, M Majetschak, O Kuss, A Sablotzki, T Feldt, J C Reidemeister, F U Schade.   

Abstract

OBJECTIVES: Cardiopulmonary bypass is associated with the release of proinflammatory cytokines (tumor necrosis factor alpha, interleukin 1beta, interleukin 6, and interleukin 8) and anti-inflammatory cytokines (interleukin 10 and transforming growth factor beta(1)). On the one hand this cytokine release is related to the postoperative systemic inflammatory response syndrome, and on the other hand it is related to deterioration of the immune system, for example in monocyte or polymorphonuclear neutrophil function, leading to an increased susceptibility to infections. To gain further insight into the alterations of immune cell reactivity and possible regulatory mechanisms, we studied lipopolysaccharide-induced tumor necrosis factor alpha synthesis in whole blood from cardiac surgical patients.
METHODS: Fifteen patients undergoing elective heart surgery with cardiopulmonary bypass were included in the study. Ex vivo lipopolysaccharide-induced tumor necrosis factor alpha synthesis was measured in a whole blood assay before, during, and after bypass. Corresponding tumor necrosis factor alpha messenger RNA levels were determined by semiquantitative reverse transcriptase-polymerase chain reaction. In addition, the influence of patient serum on whole blood responsiveness and its relationship to anti-inflammatory cytokines were evaluated in vitro.
RESULTS: Tumor necrosis factor alpha synthesis was significantly reduced after 30 minutes of cardiopulmonary bypass and showed the lowest values at the end of bypass (mean +/- SD 0.109 +/- 0.105 ng/10(6) white blood cells after 30 minutes of bypass and 0.050 +/- 0.065 ng/10(6) white blood cells at the end of bypass, vs 0.450 +/- 0.159 ng/10(6) white blood cells preoperatively, P <.001). As a further indication of reduced cytokine biosynthesis, diminished messenger RNA levels for tumor necrosis factor alpha were detected. Serum withdrawn from patients at the end of cardiopulmonary bypass reduced tumor necrosis factor alpha synthesis in heterologous blood from healthy volunteers highly significantly to 39.93% +/- 23.18% relative to control serum (P =.005) and preoperatively drawn serum (P =.024). This effect was dose dependent and was not specific for lipopolysaccharide-induced tumor necrosis factor alpha synthesis. Anesthesia and heparin administration did not influence tumor necrosis factor alpha production significantly. Ex vivo tumor necrosis factor alpha synthesis was negatively related to interleukin 10 serum levels, positively but weakly related to interleukin 4, and was not related to transforming growth factor beta(1) (Spearman correlation coefficients -0.565, P <.001, 0.362, P <.001, and -0.062, P =.460, respectively). However, interleukin 10 levels in patient serum after cardiopulmonary bypass were 300-fold below the quantities needed for half-maximal inhibition of tumor necrosis factor alpha synthesis in vitro. Moreover, the inhibitory activity could not be removed by immune absorption of interleukin 10.
CONCLUSIONS: These results suggest that during cardiac operations cytokine-inhibitory serum activities are released or newly formed. These activities could not be explained by the actions of interleukins 4 and 10 or transforming growth factor beta(1). Although their exact nature remains undetermined, these substances may contribute to the diminished immune cell functions after cardiopulmonary bypass and thus need further characterization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202878     DOI: 10.1067/mtc.2002.122300

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Effect of low-dose ketamine on post-operative serum IL-6 production among elective surgical patients: a randomized clinical trial.

Authors:  Tonny Stone Luggya; Tony Roche; Lameck Ssemogerere; Andrew Kintu; John Mark Kasumba; Arthur Kwizera; Jose Vb Tindimwebwa
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

2.  Complete Resolution of Wegener's Granulomatosis Lung Granuloma After Aortic Root Replacement.

Authors:  Sarah-Jayne Edmondson; Saina Attaran; Ulrich P Rosendahl
Journal:  Aorta (Stamford)       Date:  2016-02-01

3.  Influence of surgical intervention in the immune response of severely injured patients.

Authors:  Sascha Flohé; Sven Lendemans; Fritz-Ulrich Schade; Ernst Kreuzfelder; Christian Waydhas
Journal:  Intensive Care Med       Date:  2003-11-07       Impact factor: 17.440

4.  The effect of conventional and mini-invasive cardiopulmonary bypass on neutrophil activation in patients undergoing coronary artery bypass grafting.

Authors:  Martina Kolackova; Jan Krejsek; Vladimir Svitek; Pavel Kunes; Jiri Mandak; Zdenka Holubcova; Vladimir Lonsky
Journal:  Mediators Inflamm       Date:  2012-02-19       Impact factor: 4.711

5.  STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass.

Authors:  Petrus R de Jong; Alvin W L Schadenberg; Theo van den Broek; Jeffrey M Beekman; Femke van Wijk; Paul J Coffer; Berent J Prakken; Nicolaas J G Jansen
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

6.  Does cardiac surgery in newborn infants compromise blood cell reactivity to endotoxin?

Authors:  Kathrin Schumacher; Stefanie Korr; Jaime F Vazquez-Jimenez; Götz von Bernuth; Jean Duchateau; Marie-Christine Seghaye
Journal:  Crit Care       Date:  2005-08-09       Impact factor: 9.097

7.  Captopril Pretreatment Produces an Additive Cardioprotection to Isoflurane Preconditioning in Attenuating Myocardial Ischemia Reperfusion Injury in Rabbits and in Humans.

Authors:  Yi Tian; Haobo Li; Peiyu Liu; Jun-mei Xu; Michael G Irwin; Zhengyuan Xia; Guogang Tian
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.